Paul Berns is the co-founder, chairman and CEO of Neumora. As a managing director at ARCH Venture Partners, Paul brings deep business expertise across venture capital, biopharmaceuticals and biotechnology. He currently serves as chairman of the board of Epirium Bio, and is on the board of directors of Jazz Pharmaceuticals, EQRx and UNITY Biotechnology.
Prior to ARCH, Paul built and led three pharmaceutical companies that were acquired by some of the sector’s leading companies. He served as president, CEO and chairman of the board of Anacor Pharmaceuticals, acquired by Pfizer in 2016; president, CEO and board member of of Allos Therapeutics, acquired by Spectrum Pharmaceuticals in 2012; and president, CEO and a director of Bone Care International, acquired by Genzyme Corporation in 2005. Paul also spent several years as a self-employed consultant to the pharmaceutical industry. Earlier in his career, he held numerous roles in pharmaceuticals, including vice president and general manager of the immunology, oncology and pain therapeutics business unit of Abbott Laboratories; vice president, marketing of BASF Pharmaceuticals/Knoll (acquired by Abbot Laboratories); and various positions, including senior management roles, at Bristol Myers Squibb.
Paul holds a B.S. in Economics from the University of Wisconsin.